Dr. Huaxin Liao had his undergraduate study in medicine in the Shanghai Medical University, received his PhD from University of North Carolina at Chapel Hill (UNC-CH), and completed his postdoctoral research at Duke University, USA. Prior to returning to China, Dr. Liao was a faculty member and professor in the Duke University Medical Center, and the research director of the Duke Human Vaccine Institute.
In his over 30-years of extensive scientific research career, as a principal investigator, Dr. Liao has received numerous research grants from the funding institutions from US and China. Dr. Liao’s scientific research has been focused on virology, immunology and vaccinology especially on AIDS vaccines, has demonstrated record of successful and productive research projects and has published more than 240 scientific research papers in peer-reviewed scientific journals including Nature, Science, Cell and other top tier journals, and has hold more than 50 US, China and other international patents.
Dr. Huaxin Liao with Mr. Weihong Zheng co-founded the Trinomab Biotech Co., Ltd (Trinomab) and is currently the Chairman & CTO with responsibility of company strategic oversight and R&D development.
Mr. Weihong Zheng received an EMBA from the Peking University HSBC Business School. He was the General Manager of Oasis Pharmaceutical Co., Ltd, a subsidiary of Chia Tai Pharmaceutical Group (HK01177) and has been engaged in sales, marketing and management in medically related business for over 20 years. He has previously also successfully founded and managed several innovative biotech companies, with rich experience in business strategy and management.
Mr. Zheng with Dr. Huaxin Liao co-founded the Trinomab Biotech Co., Ltd (Trinomab), and is the CEO & President with responsibility of the company’s operation and management, strategic planning and investment as well as financing.
Wanmei Wang graduated from Southern Medical University and received her Doctor of Science degree from the Royal Hospital of Copenhagen University in Denmark. Dr. Wanmei Wang has extensive experience in investigational new drug clinical protocol design, IND to Phase I-III clinical trial development, NDA and global regulatory agency communication and negotiation.
Prior to joining Trinomab, Dr. Wanmei Wang was the General Manager of R&D at Ferring Pharmaceuticals, China, a multinational company, where she was responsible for establishing, running and managing an international pharmaceutical study site in Beijing, China, and she built a strong clinical development pipeline in China at the same time, driving eight clinical development programs to complete studies from Phase I to Phase III. She also served as Clinical Vice President at CStone Pharmaceuticals, where She was responsible for project management, clinical development strategy formulation, drug safety alerts, and analysis of medical trends and clinical study dynamics, and made significant contributions to the successful launch of several CStone Pharmaceuticals products.
In 2021, Dr. Wanmei Wang joined Trinomab as Chief Medical Officer and Senior Vice President, responsible for clinical development, registration strategy and clinical operations management of Trinomab's product pipeline in China, the U.S. and around the world.
Gang Li graduated from Shanghai Jiao Tong University and received his master's degree in biopharmaceutical engineering from East China University of Science and Technology. Working in manufacturing and quality management in the biopharmaceutical field for more than 25 years, he has led and participated in the GMP production of more than ten biological products and has led the design, construction, commissioning and validation operations of several biopharmaceutical plants.
He has successively engaged in production and quality management in Shenyang No. 1 Pharmaceutical Factory of Northeast Pharm, Shenzhen Bio Kangtai Co., Ltd., Beijing Minhai Biotechnology Co., Ltd., Livzon Group Vaccine Engineering Co., Ltd., and Zhuhai Livzon Mab Biotechnology Co., Ltd. He has a wealth of knowledge and practical experience in biotechnology, aseptic technology, GMP, engineering construction, safety and environmental management, etc., as well as extensive experience in commercial large-scale production, technology transfer, and pilot scale-up of genetically engineered protein drugs, genetically engineered vaccines, bacterin and viral vaccines, and monoclonal antibody drugs. He is proficient in the requirements of domestic drug GMP, registration regulations and technical guidelines, European and American drug GMP and other related requirements, and has experienced a number of domestic and international quality audits.
He joined Trinomab in 2019 and was responsible for the construction and operation of the company's antibody production facility, driving technology transfer, clinical sample production, manufacturing process validation for each item in the product pipeline through to commercial production.
Dr. Ahmed BOUZIDI graduated from the University of New Hampshire, USA, with a PhD in Biological Sciences and an MBA. He has been engaged in the biopharmaceutical industry since 1988, focusing on the fields of immunology, oncology, and infectious disease treatment and prevention.
Ahmed is Senior Associate of the Royal Society of Medicines. He previously founded and led several successful innovative biotech companies. He also was the President of the European Biopharmaceutical Enterprises (EFPIA group), and a board member of Vaccines Europe. Prior, Ahmed has held positions of increasing seniority in the Biotech and R&D Departments at the LFB for over 10 years. He has an extensive experience in innovative drug R&D, company management, business development and international BD project partnerships.
Dr. Ahmed BOUZIDI has recently jointed Trinomab and is the Vice President of Trinomab and the General Manager of the Trinomab, Europe and is responsible for international business development and co-operation of the company with emphasis in the European region and Western world.
Chengming Li received his Ph.D. in cell biology from North Carolina State University (NCSU). In 2003, he joined the internationally renowned company Bayer as a senior researcher.
He has been engaged in the cloning and expression of pharmaceutical molecules such as long-acting recombinant coagulation-factor-VIII and plasminogen for ten years, and has obtained a number of patent authorizations. In addition, Dr. Li also presided over and participated in the establishment, recombinant expression and production of cell lines for several recombinant protein products.
As a high-level professional introduced by the company from Bayer in the United States, Dr. Li is mainly responsible for the establishment and operation of the company's CLD department, and now is responsible for the company's CMC pre-clinical development.
Dr. Meizhuo Zhang graduated from Fudan University with a major in chemistry. She obtained master's degree in applied mathematics and computer science and a doctorate degree in computer science from the University of Houston in the United States, and then did postdoctoral research at Yale University in the United States.
Before joining Trinomab, Dr. Zhang Meizhuo served as the head of biostatistics and bioinformatics departments in well-known biopharmaceutical companies such as Bayer and AstraZeneca, providing innovative statistical and informatics solutions for drug development. She participated in and designed a number of clinical trials to support the development of new drugs. She has nearly 20 years of experience in clinical data statistical analysis, data mining, data management and clinical trial design.
After joining Trinomab, she is mainly responsible for the trial design, data management and statistical analysis of clinical studies in the company's multiple international centers.